U.S. markets closed
  • S&P 500

    3,453.49
    +17.93 (+0.52%)
     
  • Dow 30

    28,363.66
    +152.84 (+0.54%)
     
  • Nasdaq

    11,506.01
    +21.31 (+0.19%)
     
  • Russell 2000

    1,630.25
    +26.48 (+1.65%)
     
  • Crude Oil

    40.61
    +0.58 (+1.45%)
     
  • Gold

    1,906.50
    -23.00 (-1.19%)
     
  • Silver

    24.83
    -0.42 (-1.65%)
     
  • EUR/USD

    1.1826
    -0.0041 (-0.34%)
     
  • 10-Yr Bond

    0.8480
    +0.0320 (+3.92%)
     
  • GBP/USD

    1.3087
    -0.0057 (-0.43%)
     
  • USD/JPY

    104.8500
    +0.2900 (+0.28%)
     
  • BTC-USD

    13,108.99
    +2,051.98 (+18.56%)
     
  • CMC Crypto 200

    264.07
    +7.97 (+3.11%)
     
  • FTSE 100

    5,785.65
    +9.15 (+0.16%)
     
  • Nikkei 225

    23,474.27
    -165.19 (-0.70%)
     

Stay-At-Home Stock Play Teladoc Set For Q3 Beat, DA Davidson Says In Bullish Initiation

Shanthi Rexaline
·2 mins read

The telehealth company Teladoc Health Inc (NYSE: TDOC) has posted strong gains during the coronavirus pandemic.  

The Teladoc Analyst: D.A. Davidson analyst Hannah Baade initiated coverage of Teladoc with a Buy rating and $250 price target.

The Teladoc Thesis: Teladoc, being a pure play software company directly benefiting from COVID-19, is growing at a more than 60% pace organically, Baade said in an initiation note.

Telehealth utilization soared to 16% during COVID-19, and it could go up to 25% in the long term, equating to a $250-billion market going forward, the analyst said.

Acquisitions have further expanded markets and provided leverage to popular direct-to-consumer markets, she said.

Teladoc has completed 11 acquisitions that either expand its  product offerings or customer base, Baade said.

The impending Livongo Health Inc (NASDAQ: LVGO) acquisition significantly enhances the business model, supported by adding millions of new members and a new class of disease monitoring, the analyst said.

"Competitively, no other company has the scale and depth of solutions as Teladoc and we expect the company to remain firmly ahead of the curve as it continues to grow both organically and inorganically."

Additionally, Teladoc's relatively conservative guidance for the September quarter sets it up for a likely beat, she said.

The consensus revenue estimate of $281.4 million is already above the $280-million midpoint of the guidance range, Baade said.

Given the faster growth assumptions relative to peers, the premium valuation that Teladoc shares command is justified, according to D.A. Davidson. 

TDOC Price Action: At last check, Teladoc shares were rising 6.37% to $215.56.

Related Links:

7 Reasons Why This Teladoc Health Analyst Is Turning Bullish

Vivus Shares Rally On Accelerated Telemedicine Launch

Latest Ratings for TDOC

Date

Firm

Action

From

To

Sep 2020

DA Davidson

Initiates Coverage On

Buy

Aug 2020

Credit Suisse

Upgrades

Neutral

Outperform

Jul 2020

Piper Sandler

Maintains

Overweight

View More Analyst Ratings for TDOC
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.